Skip to main content

Table 2 BCVA and CMT at the base line and after 6 months of follow up

From: Pilot study of ziv-aflibercept in myopic choroidal neovascularisation patients

 

Total number of examined eyes

n = 20

Age of the studied cases

Test of significance (between age groups)

< 40 years

n = 8

≥ 40 years

n = 12

BCVA Before injection

 Mean ± S. D

0.77 ± 0.28

0.88 ± 0.28

0.60 ± 0.21

t1 = 2.56

 Range

0.4–1.4

0.4–1.4

0.4–1

p = 0.0197

BCVA After 6 months

 Mean ± S. D

0.42 ± 0.24

0.48 ± 0.23

0.33 ± 0.24

t1 = 1.392

 Range

0.1–1

0.22–1

0.1–0.7

p = 0.181

 t2

17.609

14.443

5.998

 

 P value

0.001*

0.001*

0.028*

 

CMT (um) Before injection

 Mean ± S. D

247.95 ± 25.24

242.88 ± 23.83

251.33 ± 26.60

t1 = 0.724

 Range

212–289

212–289

213–287

p = 0.478

CMT (um) After 6 months

 Mean ± S. D

194.70 ± 16.11

191.13 ± 13.83

197.08 ± 17.64

t1 = 0.802

 Range

165–235

165–210

175–235

p = 0.433

 t2

63.252

28.223

34.663

 

 P value

0.001*

0.001*

0.001*

 
  1. BCVA Best corrected visual acuity, CMT Central macular thickness, No Number, S.D Standard deviation, t1 Student t test, t2 Paired t test
  2. *p value